As South Korea’s Curocell Inc. looks to develop the country’s first homegrown CAR T-cell therapy, CEO Gunsoo Kim highlighted rising and falling trends in the global CAR T development space at Bio Korea 2024.
As South Korea’s Curocell Inc. looks to develop the country’s first homegrown CAR T-cell therapy, CEO Gunsoo Kim highlighted rising and falling trends in the global CAR T development space at Bio Korea 2024.
Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
In a recent study, researchers from Technische Universität Dresden and affiliated organizations evaluated the novel small-molecule inhibitor of the CBP/p300 HAT domain, A-485, as a potential therapeutic candidate for the treatment of hematological cancers and other pathologies related to blood leukocyte compartment.
Six weeks after the U.S. FDA issued an alert, the EMA is following suit and starting a review of the safety of six approved CAR T-cell cancer therapies, following 23 reports of patients developing secondary cancers. The EMA said such malignancies were considered “an important potential risk” at the time of approval and are included in the risk management plan. Close monitoring is in place, with companies required to conduct long-term safety and efficacy follow-up studies and to file safety update reports.
Beigene Ltd. has identified heterocyclic compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of hematologic cancer and glioblastoma.
Intelligent Omics Ltd. has established a target discovery collaboration with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of hematological cancers.
C4x Discovery Holdings plc has announced further progress in its MALT1 inhibitor program for cancer. Building on anti-cancer activity in a preclinical xenograft study, the company completed a preclinical study demonstrating its MALT1 lead compounds were free of UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) liability shown by competitor chemistries. The program is continuing to identify a shortlist of preclinical candidates for further development, and a partnering program has been initiated.
Trueline Therapeutics Inc., a subsidiary of Anji Pharmaceuticals Inc., has successfully completed IND-enabling studies with Mcl-1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers. The company is now on track to initiate clinical development.
